News
Baseline BMI may play a significant role in improving exercise capacity, body weight and BP among patients with HF with ...
In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...
Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...
Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.
Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular ...
Weight-loss injections, including popular drugs like Wegovy and Mounjaro, may offer a protective shield against serious ...
Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.
GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...
Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.
The Mounjaro buzz is now distinctly reaching Indian A-listers and wellness-conscious urban adults, sparking conversations about its potential ...
GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...
For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results